Gianni Chessari,Ian R. Hardcastle,Jong Sook Ahn,Burcu Anil,Elizabeth Anscombe,Ruth H. Bawn,Luke D. Bevan,Timothy J. Blackburn,Ildiko Buck,Celine Cano,Benoit Carbain,Juan Castro,Ben Cons,Sarah J. Cully,Jane A. Endicott,Lynsey Fazal,Bernard T. Golding,Roger J. Griffin,Karen Haggerty,Suzannah J. Harnor,Keisha Hearn,Stephen Hobson,Rhian S. Holvey,Steven Howard,Claire E. Jennings,Christopher N. Johnson,John Lunec,Duncan C. Miller,David R. Newell,Martin E. M. Noble,Judith Reeks,Charlotte H. Revill,Christiane Riedinger,Jeffrey D. St. Denis,Emiliano Tamanini,Huw Thomas,Neil T. Thompson,Mladen Vinković,Stephen R. Wedge,Pamela A. Williams,Nicola E. Wilsher,Bian Zhang,Yan Zhao,Mladen Vinković

Abstract:Inhibition of murine double minute 2 (MDM2)-p53 protein–protein interaction with small molecules has been shown to reactivate p53 and inhibit tumor growth. Here, we describe rational, structure-guided, design of novel isoindolinone-based MDM2 inhibitors. MDM2 X-ray crystallography, quantum mechanics ligand-based design, and metabolite identification all contributed toward the discovery of potent in vitro and in vivo inhibitors of the MDM2-p53 interaction with representative compounds inducing cytostasis in an SJSA-1 osteosarcoma xenograft model following once-daily oral administration.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02188?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02188</a>.Molecular formula string (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_001.csv">CSV</a>)Model of the X-ray crystal structure of MDM2 with compound 4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_002.cif">CIF</a>)Structure factors of the X-ray crystal structure of MDM2 with compound 4 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_003.cif">CIF</a>)Additional experimental details for compounds not included in the main section and analytical data for all compounds and intermediates; NMR studies on 5; X-ray structure tables; and computational chemistry (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02188/suppl_file/jm0c02188_si_004.pdf">PDF</a>)This article has not yet been cited by other publications.

Design, Synthesis and Biological Evaluation of Novel MDH Inhibitors Targeting Tumor Microenvironment

Small Molecules Simultaneously Inhibiting P53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (hdacs): Discovery of Novel Multitargeting Antitumor Agents

A Novel Malate Dehydrogenase 2 Inhibitor Suppresses Hypoxia-Inducible Factor-1 by Regulating Mitochondrial Respiration

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirotetrahydrothiopyran-Oxindole Derivatives As Potent P53-Mdm2 Inhibitors

Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents

Design, Synthesis and Biological Evaluation of HDAC and VEGFR Dual Inhibitors as a Multi-targeted Anticancer Agents

Design, Synthesis and Biological Evaluation of Biphenyl-1,2,3-Triazole Hybrid Analogues as PD-1/PD-L1 Inhibitors

Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors

Design, Synthesis and Biological Evaluation of Novel 2,4-Diaryl Pyrimidine Derivatives As Selective EGFRL858R/T790M Inhibitors.

Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirodihydrothiopyran-Oxindole Derivatives

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

Design, Synthesis, Antitumor Activity Evaluation, and Molecular Dynamics Simulation of Some 2-Aminopyrazine Derivatives

Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer

Design, synthesis and bioevaluation of dual EGFR-PI3Kα inhibitors for potential treatment of NSCLC

Design, synthesis and biological evaluation of novel pyrrolidone-based derivatives as potent p53-MDM2 inhibitors

Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors

Design, Synthesis and Biological Evaluation of Novel Thiazole-Derivatives As Mitochondrial Targeting Inhibitors of Cancer Cells.

Design and Synthesis of New Hybrids from 2-Cyano-3,12-dioxooleana- 9-Dien-28-oic Acid and O2-(2,4-dinitrophenyl) Diazeniumdiolate for Intervention of Drug-Resistant Lung Cancer.

Development of 1,5-diarylpyrazoles as EGFR/JNK-2 dual inhibitors: design, synthesis, moleecular docking, and bioactivity evaluation

Design, synthesis and biological evaluation of novel modified dual-target shikonin derivatives for colorectal cancer treatment